Slow Growth And Tough Market Make China An Intriguing Puzzle For Indian Companies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies
You may also be interested in...
Down But Not Out, Ranbaxy Eyes Generics Blockbuster Launches In China
Fierce competition makes China a tough nut to crack for generics, something India’s largest drug manufacturer Ranbaxy says it has learned the hard way, but after walking away from a joint venture, the firm is ready to try again.
Dr. Reddy’s Eyes Big Splash In China Market With A Three-fold Sales Jump
After a prolonged wait, Dr. Reddy’s finally finds rhythm in the worlds’ fastest growing market and eyes growth in niche areas.
Daiichi Sankyo Buys Out China Shell Company To Breathe New Life Into Ranbaxy
While Daiichi Sankyo has relied on Ranbaxy's sales presence in other emerging markets, it has decided to buy a stake in China to give Ranbaxy's portfolio a second chance in the country.